Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
A blogger's speculation that pSivida might be in line for a buyout bid sends the ophthalmology company's shares up nearly 4% today to a 52-week high. Shares of ophthalmology company pSivida (NSDQ:PSDV) hit a 52-week high today on speculation from a Seeking Alpha blogger that it's ripe for an acquisition this year. PSDV shares hit $3.96 each today, a 52-week high, having gained some 15.5% since a blogger writing as "Bob's Stocks" published the rumor yesterday. According to the blogger's calculations, pSivida stands to reap revenues of $315 million annually from sales of its Iluvien drug/device combination for treating diabetic macular edema.
Help employers find you! Check out all the jobs and post your resume.
A blogger's speculation that pSivida might be in line for a buyout bid sends the ophthalmology company's shares up nearly 4% today to a 52-week high. Shares of ophthalmology company pSivida (NSDQ:PSDV) hit a 52-week high today on speculation from a Seeking Alpha blogger that it's ripe for an acquisition this year. PSDV shares hit $3.96 each today, a 52-week high, having gained some 15.5% since a blogger writing as "Bob's Stocks" published the rumor yesterday. According to the blogger's calculations, pSivida stands to reap revenues of $315 million annually from sales of its Iluvien drug/device combination for treating diabetic macular edema.
Help employers find you! Check out all the jobs and post your resume.
